PATENT CLAIM ANALYSIS

Application Number: 16002686
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-05
Patent Classification: ["514", "279000"]

Abstract:
Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin a and rifaximin 3, and a poorly crystalline form referred to as rifaximin γ, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention.

Claim (Index 2):
A pharmaceutical composition comprising rifaximin in polymorphic form \u03b2.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 94.0
- Lexical Diversity: 1.73016
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['12119622', '13679602', '13041347', '11873841', '13041348']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7369085535011953
- 35 USC 102 Novelty (BERT): 0.5207149927059085
- Combined Prediction Score: 0.7152891974216666
- Mean Citation Score: 274.71607000000006
- Max Citation Score: 284.16348
- Similarity Product: 185.93093544519425

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test